wcg Avoca

BioWa, Inc. is a New Jersey-based biotech company and a wholly owned subsidiary of Kyowa Kirin Co, Ltd. Established in 2003, BioWa is dedicated to advancing health through innovations in life science and technology, specializing in the out-licensing of Kyowa Kirin's Therapeutic Antibody Technologies, POTELLIGENT and COMPLEGENT. The company's name, BioWa, symbolizes the harmonious fusion of American and Japanese sensibilities, reflecting their earnest mission to enhance the quality of life for all. As the exclusive worldwide licensor of POTELLIGENT Technology, BioWa offers a proprietary technology that generates fucose-free monoclonal antibodies with significantly increased antibody-dependent cellular cytotoxicity (ADCC), bolstering the immune system's ability to eliminate tumor cells. Additionally, BioWa holds the exclusive global license for COMPLEGENT Technology, a robust platform that enhances complement-dependent cytotoxicity (CDC) of therapeutic antibodies. By combining these technologies, BioWa introduces the AcrretaMab platform, a novel class of antibodies designed to combat various life-threatening diseases, including cancer.Generated from the website

Otsuka America Pharmaceutical, based in Princeton, NJ, is a healthcare company driven by a strong purpose and defined beliefs. They are committed to serving communities, advocating for caregivers, and empowering their employees to transcend expectations and go above and beyond for patients and families. With a focus on research and development, Otsuka works on innovative products and resources to advance healthcare, including collaborations with other organizations. Their unwavering belief in perseverance, unconventional thinking, and humility guides their mission to defy limitations and make a positive impact on global health. Generated from the website

eVenus Pharmaceutical Laboratories Inc., established in 2009 as a wholly owned subsidiary of Jiangsu Hengrui Medicine Co. Ltd., is based in Princeton, New Jersey. The company specializes in filing regulatory applications with the US FDA and aims to provide high-quality, affordable drug substances and products, encompassing both generic and branded medicine portfolios. With a manufacturing and development history exceeding 40 years, Jiangsu Hengrui Medicine Co. Ltd. supports eVenus's extensive capabilities, enabling it to maintain one of the most aggressive DMF and finished product pipelines in the industry. eVenus aspires to be a premier global pharmaceutical company dedicated to improving the quality of life through safe and effective medicines that meet customer needs worldwide. Generated from the website